Subscribe Now

By entering these details you are signing up to receive our newsletter.

  • To use more accessibility options, please use a different browser such as Chrome or Firefox.

New IN this week

VIEW MORE >

Rare disease therapies framework: industry urged to contribute to MHRA consultation on plans for regulatory changes

By Julie Penfold, RARE Revolution
13 July 2026

The Act for Ultra-Rare Coalition – growing momentum for an overlooked population

By Emma Bishop, RARE Revolution
13 July 2026

IN the know

VIEW MORE >

The Act for Ultra-Rare Coalition – growing momentum for an overlooked population

By Emma Bishop, RARE Revolution
13 July 2026

Who decides what your health is worth?

By Henry Burkitt, Oxygen Strategy
6 July 2026

RARE Revolution poll results reveal Rare Disease Day campaigns helped reach more people

By Karen Roberts, RARE Revolution
6 July 2026

Thinking deeply when thinking is hardest: the psychology of joining a clinical trial

By Keith Berelowitz, trialport
22 June 2026

INnovation

VIEW MORE >

Understanding comes first, decisions follow: trialport brings clarity to the clinical trial environment

By Emma Bishop, RARE Revolution
1 June 2026

The failure of the ‘usual suspects’ approach to life science recruitment

By CONTRIBUTOR
18 May 2026

From months to weeks: how The BioForge is using AI to unblock the slowest part of drug development

By Emma Bishop, RARE Revolution
11 May 2026

The evidence that trials leave behind: Vitaccess and the MGFA look to address this gap in myasthenia gravis

By Emma Bishop, RARE Revolution
13 April 2026

Women IN RARE

VIEW MORE >

Charlene Son Rigby, chief executive officer, Global Genes

By CONTRIBUTOR
29 June 2026

Deborah O’Neil, chief executive officer, NovaBiotics Ltd

By CONTRIBUTOR
11 May 2026

Gemma Gapper, director, Policy & Patient Access UK & Ireland, BioCryst a Neopharmed Gentili company

By CONTRIBUTOR
27 April 2026

Donna M Sullivan, founder and executive director, ElevateRARE

By CONTRIBUTOR
6 April 2026

INcognito

VIEW MORE >

incognito: the secret life of a…charity CEO

By CONTRIBUTOR
29 June 2026

incognito: the secret life of a…rare disease parent and charity founder

By CONTRIBUTOR
16 February 2026

incognito: the secret life of an…independent patient engagement consultant to industry

By CONTRIBUTOR
2 February 2026

incognito: the secret life of a…rare disease board trustee

By CONTRIBUTOR
25 August 2025

IN the thick of it

VIEW MORE >

Putting you in the heart of the rare community – The Sturge-Weber Foundation

By CONTRIBUTOR
6 July 2026

Putting you in the heart of the rare community – Wolfram Syndrome UK

By CONTRIBUTOR
15 June 2026

Putting you in the heart of the rare community – Stichting TAPS Support

By CONTRIBUTOR
25 May 2026

Putting you in the heart of the rare community – CMTUK

By CONTRIBUTOR
4 May 2026

IN person

VIEW MORE >

Rare disease therapies framework: industry urged to contribute to MHRA consultation on plans for regulatory changes

By Julie Penfold, RARE Revolution
13 July 2026

Next steps for rare diseases in England: advancing research, innovation, trials and genomics

By Julie Penfold, RARE Revolution
22 June 2026

Drug repurposing: translating optimism into action for rare diseases

By Rebecca Stewart, RARE Revolution
15 June 2026

Next steps for rare diseases in England: progress of the Rare Therapies Launch Pad

By Julie Penfold, RARE Revolution
15 June 2026

IN the pipeline

VIEW MORE >

Releasing the brake: how an oral therapy could transform life with achondroplasia

By Nicola Miller, RARE Revolution
20 April 2026

Parent-led: the FOXG1 Research Foundation’s path from diagnosis to drug development

By Nicola Miller, RARE Revolution
30 March 2026

Rethinking cell therapy: CERo Therapeutics brings a new mechanism to AML

By Nicola Miller, RARE Revolution
23 March 2026

Turning point: FORTIFY phase 3 study for limb-girdle muscular dystrophy

By Nicola Miller, RARE Revolution
1 December 2025
Skip to content